Molecular Biology Program
The Simon Powell Lab
Research
The major theme of our work is how DNA repair processes are disrupted in human cancers and how this can be exploited therapeutically. The biologically significant DNA damage caused by ionizing radiation and a number of cytotoxic drugs requires double-strand break repair for survival. We have largely focused on the role of double-strand break repair and homologous recombination in particular.
Research Projects
Featured News
Publications
Lok BH, Carley AC, Tchang B, Powell SN. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene. 2012 Sep 10. doi: 10.1038/onc.2012.391. [Epub ahead of print] [PMID: 22964643].
People
Simon N. Powell, MD, PhD
- Molecular biologist Simon Powell investigates DNA replication and recombination, chromosome dynamics, and human genetics.
- PhD, MD, University of London
- powells@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Postdoctoral Research Fellow in Molecular Biology/Radiation Oncology
There are currently two postdoctoral research fellow positions available within the laboratory of Simon Powell.
Get in Touch
-
Lab Head Email
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Simon N. Powell discloses the following relationships and financial interests:
-
Artios Pharam Limited
Provision of Services (uncompensated) -
AstraZeneca
Provision of Services -
Elekta
Provision of Services
-
PharmaPier US LLC
Provision of Services (uncompensated) -
Rain Therapeutics Inc.
Provision of Services (uncompensated) -
Varian Medical Systems
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.